Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

REMEVi vs TeleHealth Med

REMEVi
Graded #105

Higher grade

vs+4.300000000000011
TeleHealth Med
Graded #210

Lower grade

The verdict

REMEVi takes it — 70.4/100 to 66.1/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTeleHealth Med +20
54
74
Dose & formulationREMEVi +1
64
63
Clinical oversightREMEVi +10
86
76
Labs & monitoringREMEVi +13
65
52
FulfillmentREMEVi +34
97
63
Contract termsREMEVi +14
69
55
REMEVi · left barTeleHealth Med · right bar

The numbers

MetricREMEViTeleHealth Med
WeighScore70.4/10066.1/100
GradeCC
Scorecard rank#105#210
Semaglutide$199/mo (starting dose, compounded)$147/mo (starting dose, compounded)
Tirzepatide$269/mo (starting dose, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
REMEVi

Graded #105 · C

Strengths

  • The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
  • Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
  • LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
  • Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)

Where it loses points

  • Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
  • The specific compounding pharmacy is not named (described as 'NPI-verified')
  • A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements
TeleHealth Med

Graded #210 · C

Strengths

  • Corporate entity disclosed (TeleHealth Med, Inc.) — clearer accountability than undisclosed competitors
  • Publishes the FDA compounded-medication disclaimer
  • 503A pharmacy designation stated in the FAQ
  • Honest disclosure that testimonials are compensated and results aren't independently verified
  • Both injectable and sublingual forms offered

Where it loses points

  • Specific 503A pharmacy partner not named
  • LegitScript ID number not shown in text — only a verification link
  • Full states-served list not disclosed
  • Named medical director not disclosed
  • Dose tiers beyond the $147/mo starting price not published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard